More people are now focused on near-term revenues. They're focused on a path to profitability and they want to make money. It's not the 12 to 15 years of promises that you see in the typical conventional drug discovery companies. There has been a lot of market volatility lately. A lot of people are very focused on the information coming out of the human genome project, and certainly we are one of those people.
People believe biotechnology is becoming much more like information technology.
We have this code that we can treat as a data set. The real driver for the next 10 to 20 years is going to be the information that comes out of this mountain of human genomic data. We're going to ensure that they're capitalized well, and again, not take the management risk on underwriting someone's development. We've actually got two funds. We encourage your comments.